HORIZON_OLE
A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial
- Stage
- inclusie
- Medicine
- Population
- Primaire preventie coronairlijden
- Phase
- IIIb
- First Patient In
- 5 June 2026
- Last Patient In
- -
- Last Patient Last Visit
- -
Inclusion period
Board Contact
dr. S. van Wijk
Cardioloog
Office Contact
